RHB-105 + Active Comparator
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Helicobacter Pylori Infection
Conditions
Helicobacter Pylori Infection, Dyspepsia
Trial Timeline
Jun 18, 2017 → Dec 13, 2018
NCT ID
NCT03198507About RHB-105 + Active Comparator
RHB-105 + Active Comparator is a phase 3 stage product being developed by RedHill Biopharma for Helicobacter Pylori Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03198507. Target conditions include Helicobacter Pylori Infection, Dyspepsia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03198507 | Phase 3 | Completed |
Competing Products
6 competing products in Helicobacter Pylori Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy | Sun Pharmaceutical | Approved | 85 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + Placebo + helicobacter pylori vaccine + helicobacter pylori vaccine | Novartis | Phase 1 | 33 |
| H.pylori vaccines + Placebo Vaccine | Novartis | Phase 1 | 33 |
| Vonoprazan + Amoxicillin + Clarithromycin + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| pantoprazole + bismuth + metronidazole + tetracycline | Pacific Biosciences | Approved | 77 |